✦ LIBER ✦

Interleukin-6 receptor inhibition with tocilizumab reduces disease activity in rheumatoid arthritis with inadequate response to disease-modifying antirheumatic drugs: The tocilizumab in combination with traditional disease-modifying antirheumatic drug therapy study

✍ Scribed by Mark C. Genovese; James D. McKay; Evgeny L. Nasonov; Eduardo F. Mysler; Nilzio A. da Silva; Emma Alecock; Thasia Woodworth; Juan J. Gomez-Reino

Publisher: John Wiley and Sons
Year: 2008
Tongue: English
Weight: 148 KB
Volume: 58
Category: Article
ISSN: 0004-3591
DOI: 10.1002/art.23940

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

The good initial response to therapy wit

The good initial response to therapy with a combination of traditional disease-modifying antirheumatic drugs is sustained over time: The eleven-year results of the Finnish rheumatoid arthritis combination therapy trial

✍ Vappu Rantalaiho; Markku Korpela; Pekka Hannonen; Hannu Kautiainen; Salme Järven 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 156 KB 👁 1 views

Phase IIb dose-ranging study of the oral

Phase IIb dose-ranging study of the oral JAK inhibitor tofacitinib (CP-690,550) or adalimumab monotherapy versus placebo in patients with active rheumatoid arthritis with an inadequate response to disease-modifying antirheumatic drugs

✍ Roy Fleischmann; Maurizio Cutolo; Mark C. Genovese; Eun Bong Lee; Keith S. Kanik 📂 Article 📅 2012 🏛 John Wiley and Sons 🌐 English ⚖ 424 KB 👁 3 views

Low-dose prednisolone in addition to the

Low-dose prednisolone in addition to the initial disease-modifying antirheumatic drug in patients with early active rheumatoid arthritis reduces joint destruction and increases the remission rate: A two-year randomized trial

✍ Björn Svensson; Annelies Boonen; Kristina Albertsson; Désirée van der Heijde; Ca 📂 Article 📅 2005 🏛 John Wiley and Sons 🌐 English ⚖ 208 KB 👁 2 views

## Abstract ## Objective To assess the efficacy of low‐dose prednisolone on joint damage and disease activity in patients with early rheumatoid arthritis (RA). ## Methods At the start of their initial treatment with a disease‐modifying antirheumatic drug (DMARD), patients with early (duration ≤1

Comparison of the response to infliximab

Comparison of the response to infliximab or etanercept monotherapy with the response to cotherapy with methotrexate or another disease-modifying antirheumatic drug in patients with rheumatoid arthritis: Results from the British Society for Rheumatology Biologics Register

✍ Kimme L. Hyrich; Deborah P. M. Symmons; Kath D. Watson; Alan J. Silman; British 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 90 KB 👁 2 views

## Abstract ## Objective To compare outcome at 6 months in unselected “real‐world” patients with rheumatoid arthritis treated with etanercept or infliximab as either monotherapy, cotherapy with methotrexate (MTX), or cotherapy with another disease‐modifying antirheumatic drug (DMARD). ## Methods